RESUMO
BACKGROUND: Community-acquired pneumonia (CAP) is a lung infection that can be acquired during day-to-day activities in the community (not while receiving care in a hospital). Community-acquired pneumonia poses a significant public health burden in terms of mortality, morbidity, and costs. Shorter antibiotic courses for CAP may limit treatment costs and adverse effects, but the optimal duration of antibiotic treatment is uncertain. OBJECTIVES: To evaluate the efficacy and safety of short-course versus longer-course treatment with the same antibiotic at the same daily dosage for CAP in non-hospitalised adolescents and adults (outpatients). We planned to investigate non-inferiority of short-course versus longer-term course treatment for efficacy outcomes, and superiority of short-course treatment for safety outcomes. SEARCH METHODS: We searched CENTRAL, which contains the Cochrane Acute Respiratory Infections Group Specialised Register, MEDLINE, Embase, five other databases, and three trials registers on 28 September 2017 together with conference proceedings, reference checking, and contact with experts and pharmaceutical companies. SELECTION CRITERIA: Randomised controlled trials (RCTs) comparing short- and long-courses of the same antibiotic for CAP in adolescent and adult outpatients. DATA COLLECTION AND ANALYSIS: We planned to use standard Cochrane methods. MAIN RESULTS: Our searches identified 5260 records. We did not identify any RCTs that compared short- and longer-courses of the same antibiotic for the treatment of adolescents and adult outpatients with CAP.We excluded two RCTs that compared short courses (five compared to seven days) of the same antibiotic at the same daily dose because they evaluated antibiotics (gemifloxacin and telithromycin) not commonly used in practice for the treatment of CAP. In particular, gemifloxacin is no longer approved for the treatment of mild-to-moderate CAP due to its questionable risk-benefit balance, and reported adverse effects. Moreover, the safety profile of telithromycin is also cause for concern.We found one ongoing study that we will assess for inclusion in future updates of the review. AUTHORS' CONCLUSIONS: We found no eligible RCTs that studied a short-course of antibiotic compared to a longer-course (with the same antibiotic at the same daily dosage) for CAP in adolescent and adult outpatients. The effects of antibiotic therapy duration for CAP in adolescent and adult outpatients remains unclear.
Assuntos
Antibacterianos/administração & dosagem , Pneumonia/tratamento farmacológico , Adolescente , Adulto , Infecções Comunitárias Adquiridas/tratamento farmacológico , Esquema de Medicação , Fluoroquinolonas/administração & dosagem , Gemifloxacina , Humanos , Cetolídeos/administração & dosagem , Naftiridinas/administração & dosagem , Pacientes AmbulatoriaisRESUMO
Solithromycin, a ketolide/macrolide antibiotic, has recently been reported to be free of the expected QT-prolonging effect of macrolides. It appears that its keto substitution provides a structural basis for this observation, as the other two tested ketolides also have minimal QT effect.Among non-cardiovascular therapies, antimicrobials probably carry the greatest potential to cause cardiac arrhythmias. This is a result of their propensity to bind to the delayed rectifier potassium channel, IKr, inducing QT prolongation and risk of torsades de pointes ventricular tachycardia, their frequent interference with the metabolism of other QT prolongers and their susceptibility to metabolic inhibition by numerous commonly used drugs.Unfortunately, there is evidence that medical practitioners do not take account of the QT/arrhythmia risk of antimicrobials in their prescribing practices. Education on this topic is sorely needed. When a macrolide is indicated, a ketolide should be considered in patients with a QT risk.
Assuntos
Antibacterianos/efeitos adversos , Antibacterianos/metabolismo , Síndrome do QT Longo/induzido quimicamente , Antibacterianos/química , Antibacterianos/uso terapêutico , Educação Médica/métodos , Humanos , Cetolídeos/administração & dosagem , Cetolídeos/uso terapêutico , Macrolídeos/efeitos adversos , Macrolídeos/química , Macrolídeos/uso terapêutico , Canais de Potássio Corretores do Fluxo de Internalização/metabolismo , Padrões de Prática Médica , Torsades de Pointes/induzido quimicamente , Triazóis/efeitos adversos , Triazóis/química , Triazóis/uso terapêuticoRESUMO
Without quantum theory any understanding of molecular interactions is incomplete. In principal, chemistry, and even biology, can be fully derived from non-relativistic quantum mechanics. In practice, conventional quantum chemical calculations are computationally too intensive and time consuming to be useful for drug discovery on more than a limited basis. A previously described, original, quantum-based computational process for drug discovery and design bridges this gap between theory and practice, and allows the application of quantum methods to large-scale in silico identification of active compounds. Here, we show the results of this quantum-similarity approach applied to the discovery of novel liver-stage antimalarials. Testing of only five of the model-predicted compounds in vitro and in vivo hepatic stage drug inhibition assays with P. berghei identified four novel chemical structures representing three separate quantum classes of liver-stage antimalarials. All four compounds inhibited liver-stage Plasmodium as a single oral dose in the quantitative PCR mouse liver-stage sporozoites-challenge model. One of the newly identified compounds, cethromycin [ABT-773], a macrolide-quinoline hybrid, is a drug with an extensive (over 5,000 people) safety profile warranting its exploitation as a new weapon for the current effort of malaria eradication. The results of our molecular modeling exceed current state-of-the-art computational methods. Drug discovery through quantum similarity is data-driven, agnostic to any particular target or disease process that can evaluate multiple phenotypic, target-specific, or co-crystal structural data. This allows the incorporation of additional pharmacological requirements, as well as rapid exploration of novel chemical spaces for therapeutic applications.
Assuntos
Antimaláricos/administração & dosagem , Antimaláricos/síntese química , Biologia Computacional/métodos , Reposicionamento de Medicamentos/métodos , Malária/tratamento farmacológico , Administração Oral , Animais , Antimaláricos/química , Cetolídeos/administração & dosagem , Cetolídeos/síntese química , Cetolídeos/química , Malária/parasitologia , Camundongos , Plasmodium berghei/efeitos dos fármacos , Teoria Quântica , Relação Estrutura-AtividadeRESUMO
The involvement of intestinal permeability in the oral absorption of clarithromycin (CAM), a macrolide antibiotic, and telithromycin (TEL), a ketolide antibiotic, in the presence of efflux transporters was examined. In order independently to examine the intestinal and hepatic availability, CAM and TEL (10 mg/kg) were administered orally, intraportally and intravenously to rats. The intestinal and hepatic availability was calculated from the area under the plasma concentration-time curve (AUC) after administration of CAM and TEL via different routes. The intestinal availabilities of CAM and TEL were lower than their hepatic availabilities. The intestinal availability after oral administration of CAM and TEL increased by 1.3- and 1.6-fold, respectively, after concomitant oral administration of verapamil as a P-glycoprotein (P-gp) inhibitor. Further, an in vitro transport experiment was performed using Caco-2 cell monolayers as a model of intestinal epithelial cells. The apical-to-basolateral transport of CAM and TEL through the Caco-2 cell monolayers was lower than their basolateral-to-apical transport. Verapamil and bromosulfophthalein as a multidrug resistance-associated proteins (MRPs) inhibitor significantly increased the apical-to-basolateral transport of CAM and TEL. Thus, the results suggest that oral absorption of CAM and TEL is dependent on intestinal permeability that may be limited by P-gp and MRPs on the intestinal epithelial cells.
Assuntos
Antibacterianos/farmacocinética , Claritromicina/farmacocinética , Absorção Intestinal , Mucosa Intestinal/metabolismo , Cetolídeos/farmacocinética , Subfamília B de Transportador de Cassetes de Ligação de ATP/metabolismo , Administração Oral , Animais , Antibacterianos/administração & dosagem , Antibacterianos/sangue , Disponibilidade Biológica , Células CACO-2 , Claritromicina/administração & dosagem , Claritromicina/sangue , Humanos , Cetolídeos/administração & dosagem , Cetolídeos/sangue , Fígado/metabolismo , Masculino , Proteínas Associadas à Resistência a Múltiplos Medicamentos/metabolismo , Permeabilidade , Ratos WistarRESUMO
WHAT IS KNOWN AND OBJECTIVE: Clinical pharmacokinetic profiles of clarithromycin and telithromycin in bronchopulmonary sites have not been fully characterized. This study aimed to describe in more detail the pharmacokinetics of the two macrolides in epithelial lining fluid (ELF) of human bronchi and to evaluate their pharmacodynamic target attainment at this site. METHODS: Previously reported drug concentration data for serum and ELF were simultaneously fitted to a three-compartment pharmacokinetic model using nonmem program. The model parameter estimates were used for site-specific pharmacodynamic simulation. RESULTS AND DISCUSSION: Population mean parameters for clarithromycin were as follows: distribution volumes of central, peripheral and ELF compartments (V1 /F, V2 /F and V3 /F) = 204·7, 168·9 and 67·1 L; clearance (CL/F) = 34·4 L/h; absorption rate constant (Ka ) = 0·680 1/h; transfer rate constants connecting compartments (K12 , K21 , K13 and K31 = 0·0193, 0·434, 0·667 and 0·260 1/h, respectively). Mean parameters for telithromycin were as follows: V1 /F, V2 /F and V3 /F = 370·3, 290·3 and 213·8 L; CL/F = 89·5 L/h; Ka = 0·740 1/h; K12 , K21 , K13 and K31 = 0·0026, 1·044, 0·758 and 0·158 1/h, respectively. Using these parameters, the mean ELF/serum ratio in the area under drug concentration-time curve (AUC) was 7·80 for clarithromycin and 8·05 for telithromycin. Clarithromycin achieved a ≥ 90% probability of attaining a pharmacodynamic target [AUC/minimum inhibitory concentration (MIC) = 100] in ELF against bacterial isolates for which MICs were ≤0·5 and ≤1 mg/L for twice-daily doses of 250 and 500 mg, respectively. For telithromycin, once-daily doses of 600 and 800 mg achieved a ≥90% probability in ELF against Streptococcus pneumoniae, Staphylococcus aureus and Moraxella catarrhalis isolates but not Haemophilus influenzae isolates. WHAT IS NEW AND CONCLUSION: These results should provide a better understanding of the bronchial pharmacokinetics of clarithromycin and telithromycin, while also providing useful information about their dosages for respiratory tract infections based on site-specific pharmacodynamic evaluation. Further studies in a large number of patients are needed to confirm our findings and clarify their therapeutic implications.
Assuntos
Antibacterianos/farmacocinética , Claritromicina/farmacocinética , Cetolídeos/farmacocinética , Modelos Biológicos , Antibacterianos/administração & dosagem , Área Sob a Curva , Bactérias/efeitos dos fármacos , Brônquios/metabolismo , Claritromicina/administração & dosagem , Simulação por Computador , Relação Dose-Resposta a Droga , Epitélio/metabolismo , Humanos , Cetolídeos/administração & dosagem , Testes de Sensibilidade Microbiana , Dinâmica não Linear , Infecções Respiratórias/tratamento farmacológico , Infecções Respiratórias/microbiologia , Distribuição TecidualRESUMO
The increasing prevalence of drug-resistant pathogens highlights the need to identify novel antibiotics. Here we investigated the efficacies of four new antimicrobial peptides (AMPs) for potential drug development. The antibacterial activities, synergistic effects, and antibiofilm properties of the four chimeric AMPs were tested against Acinetobacter baumannii, an emerging Gram-negative, nosocomial, drug-resistant pathogen. Nineteen A. baumannii strains resistant to ampicillin, cefotaxime, ciprofloxacin, tobramycin, and erythromycin were isolated at a hospital from patients with cholelithiasis. All four peptides exhibited significant antibacterial effects (MIC=3.12 to 12.5 µM) against all 19 strains, whereas five commercial antibiotics showed little or no activity against the same pathogens. An exception was polymyxin, which was effective against all of the strains tested. Each of the peptides showed synergy against one or more strains when administered in combination with cefotaxime, ciprofloxacin, or erythromycin. The peptides also exhibited an ability to prevent biofilm formation, which was not seen with cefotaxime, ciprofloxacin, or erythromycin, though polymyxin also inhibited biofilm formation. Indeed, when administered in combination with ciprofloxacin, the AMP HPMA exerted a potent synergistic effect against A. baumannii biofilm formation. Collectively, our findings indicate that the AMPs tested have no cytotoxicity but possess potent antibacterial and antibiofilm activities and may act synergistically with commercial antibiotics.
Assuntos
Acinetobacter baumannii/efeitos dos fármacos , Antibacterianos/farmacologia , Peptídeos Catiônicos Antimicrobianos/farmacologia , Biofilmes/efeitos dos fármacos , Infecções por Acinetobacter/tratamento farmacológico , Antibacterianos/administração & dosagem , Peptídeos Catiônicos Antimicrobianos/administração & dosagem , Cefotaxima/administração & dosagem , Cefotaxima/farmacologia , Ciprofloxacina/administração & dosagem , Ciprofloxacina/farmacologia , Farmacorresistência Bacteriana Múltipla/efeitos dos fármacos , Sinergismo Farmacológico , Humanos , Queratinócitos/efeitos dos fármacos , Queratinócitos/microbiologia , Cetolídeos/administração & dosagem , Cetolídeos/farmacologia , Testes de Sensibilidade MicrobianaRESUMO
PURPOSE: The efficacy of aerosol-based delivery of telithromycin (TEL), as a model antimicrobial agent, for the treatment of respiratory infections was evaluated by comparison with oral administration. METHOD: The aerosol formulation (0.2 mg/kg) was administered to rat lungs using a Liquid MicroSprayer. RESULTS AND DISCUSSION: The time courses of the concentration of TEL in lung epithelial lining fluid (ELF) and alveolar macrophages (AMs) following administration of an aerosol formulation to rat lungs were markedly higher than that following the administration of an oral formulation (50 mg/kg). The time course of the concentrations of TEL in plasma following administration of the aerosol formulation was markedly lower than that in ELF and AMs. These results indicate that the aerosol formulation is more effective in delivering TEL to ELF and AMs, compared to the oral formulation, despite a low dose and it avoids distribution of TEL to the blood. In addition, the antibacterial effects of TEL in ELF and AMs following administration of the aerosol formulation were estimated by pharmacokinetics/pharmacodynamics analysis. The concentrations of TEL in ELF and the AMs time curve/minimum inhibitory concentration of TEL ratio were markedly higher than the effective values. CONCLUSION: This study indicates that an antibiotic aerosol formulation may be an effective pulmonary drug delivery system for the treatment of respiratory infections.
Assuntos
Antibacterianos/administração & dosagem , Líquido Extracelular/metabolismo , Cetolídeos/administração & dosagem , Pulmão/metabolismo , Macrófagos Alveolares/metabolismo , Administração por Inalação , Animais , Antibacterianos/farmacocinética , Antibacterianos/farmacologia , Células Epiteliais/metabolismo , Haemophilus influenzae/efeitos dos fármacos , Cetolídeos/farmacocinética , Cetolídeos/farmacologia , Ratos , Ratos Sprague-Dawley , Infecções Respiratórias/tratamento farmacológico , Streptococcus pneumoniae/efeitos dos fármacos , Tecnologia FarmacêuticaRESUMO
Telithromycin and metformin have been reported to be commonly metabolized via hepatic CYP3A1/2 in rats. Community-acquired respiratory tract infection was reported to be frequent in patients with diabetes mellitus. Compared with controls, hepatic CYP3A1/2 was reported to be increased in male rats with diabetes mellitus induced by streptozotocin (DMIS rats). After the intravenous administration of both drugs together to male DMIS rats, the time-averaged non-renal clearance (CL(NR)) of metformin was significantly slower (by 33.1%; 10.3 versus 15.4 ml min(-1) kg(-1)) than metformin alone due to the inhibition of hepatic metabolism of metformin by telithromycin via CYP3A1/2. After the oral administration of both drugs together, the total area under the plasma concentration-time curve (AUC) of metformin was comparable possibly due to the increased intestinal metabolism of metformin by telithromycin.
Assuntos
Diabetes Mellitus/tratamento farmacológico , Cetolídeos/farmacocinética , Cetolídeos/uso terapêutico , Metformina/farmacocinética , Metformina/uso terapêutico , Administração Oral , Animais , Proteínas Sanguíneas/metabolismo , Diálise , Interações Medicamentosas , Injeções Intravenosas , Mucosa Intestinal/metabolismo , Cetolídeos/administração & dosagem , Cetolídeos/sangue , Masculino , Metformina/administração & dosagem , Metformina/sangue , Microssomos Hepáticos/metabolismo , Ligação Proteica , Ratos , Ratos Sprague-DawleyRESUMO
Based on clinicians' expectations of high concentrations of telithromycin (TEL) in tissues, combined with its excellent in vitro antimicrobial characteristics, TEL is casually considered as a potential therapeutic option for the therapy of minor cases of soft tissue or bite-wound infections. To clarify this clinically important issue, the present investigation was carried out to measure the pharmacokinetic profile of TEL in the interstitial space fluid (ISF) of skeletal muscle and subcutaneous adipose tissue by means of the microdialysis technique in 10 healthy subjects following repetitive daily doses of 800 mg TEL. These data were compared with free concentrations of TEL determined in plasma. External controls for the present examination were the use of historic, single-dose data collected by our study group utilising identical methods and the same trial subjects. Despite an increase in the median half-life from ca. 3 h after a single dose to ca. 10h at steady-state conditions in all compartments, accumulation of TEL in ISF of soft tissues and plasma was clinically non-relevant. Median free peak concentrations in plasma, skeletal muscle and subcutis were 0.52, 0.13 and 0.19 mg/L, respectively. The median ratios of the tissue to plasma free areas under the concentration-time curves from 0 to 24 h (fAUC(0-24) tissue/fAUC(0-24) plasma) were 0.27 and 0.58 for muscle and subcutis, respectively (P>0.05). The present multiple-dose investigation of TEL is in line with a previous single-dose study confirming that TEL 800 mg/day may not be optimally effective in the therapy of soft tissue infections.
Assuntos
Antibacterianos/farmacocinética , Cetolídeos/farmacocinética , Músculo Esquelético/química , Gordura Subcutânea/química , Adolescente , Adulto , Antibacterianos/administração & dosagem , Humanos , Cetolídeos/administração & dosagem , Masculino , Plasma/química , Distribuição Tecidual , Adulto JovemAssuntos
Antibacterianos/efeitos adversos , Cetolídeos/efeitos adversos , Miastenia Gravis/induzido quimicamente , Transtornos da Visão/induzido quimicamente , Antibacterianos/administração & dosagem , Antibacterianos/uso terapêutico , Aprovação de Drogas , Europa (Continente) , Humanos , Cetolídeos/administração & dosagem , Cetolídeos/uso terapêutico , Estados UnidosRESUMO
OBJECTIVE: This study compared the clinical efficacy, time to symptom resolution, and tolerability of a 5-day regimen of telithromycin with a 10-day regimen of high-dose amoxicillin-clavulanate in acute bacterial sinusitis (ABS). RESEARCH DESIGN AND METHODS: In this multinational (41 centers in Canada, Germany, Greece, Portugal, and Turkey), open-label, noninferiority study, patients >/=18 years old (n=298) with a clinical (>7 days' symptoms) and radiological (air/fluid level, total opacification, mucosal thickening >/=10 mm) diagnosis of ABS were randomized to receive telithromycin 800 mg once daily for 5 days or amoxicillin-clavulanate 875/125 mg twice daily for 10 days. Clinical efficacy and tolerability were assessed at the test-of-cure visit (days 17-21). Time to symptom resolution was based on patients' daily diary assessment of individual symptoms. RESULTS: The per-protocol clinical success rate (primary endpoint) with telithromycin (88.6% (109/123)) was noninferior to that with amoxicillin-clavulanate (88.8% (111/125)) (95% confidence interval: -8.9 to 8.5). In the modified intention-to-treat (mITT) population, the median time for 50% reduction of total symptom scores was significantly shorter for telithromycin (4 days) vs. amoxicillin-clavulanate (5 days; p=0.044); median times for 75% reduction of total symptom scores were: telithromycin, 7 days; amoxicillin-clavulanate, 8 days (p=0.115). The median time for reduction of total symptom scores to the absent/very mild category (mITT population) was 6 days for telithromycin vs. 8 days for amoxicillin-clavulanate (p=0.04). All treatment-emergent adverse events (TEAEs) were mostly gastrointestinal and occurred in 20.7% (30/145) of telithromycin-treated patients vs. 31.8% (47/148) of amoxicillin-clavulanate-treated patients (p=0.034). One serious AE was reported in the telithromycin group, but it was considered not to be related to treatment. CONCLUSIONS: This open-label, randomized study demonstrated that treatment of ABS with telithromycin resulted in comparable clinical efficacy, shorter times to symptom resolution, and fewer total TEAEs than treatment with amoxicillin-clavulanate.
Assuntos
Amoxicilina/administração & dosagem , Antibacterianos/administração & dosagem , Infecções Bacterianas/tratamento farmacológico , Cetolídeos/administração & dosagem , Avaliação de Resultados em Cuidados de Saúde , Sinusite/tratamento farmacológico , Doença Aguda , Adulto , Amoxicilina/farmacologia , Antibacterianos/farmacologia , Infecções Bacterianas/fisiopatologia , Esquema de Medicação , Feminino , Haemophilus influenzae/efeitos dos fármacos , Humanos , Cetolídeos/farmacologia , Masculino , Pessoa de Meia-Idade , Qualidade de Vida , Sinusite/fisiopatologia , Streptococcus pneumoniae/efeitos dos fármacos , Inquéritos e Questionários , Resistência beta-Lactâmica/efeitos dos fármacosRESUMO
PURPOSE: It has been reported that telithromycin is primarily metabolized via hepatic CYP3A1/2 in rats, the expression and/or mRNA level of hepatic CYP3A1/2 increase in rat model of diabetes mellitus induced by alloxan (DMIA) or streptozotocin (DMIS), and intestinal CYP3A1/2 enzyme activity decreases in rat model of DMIS. Thus, the pharmacokinetic changes of telithromycin in both models of diabetes mellitus compared with those in the control rats were evaluated. METHODS: Telithromycin was administered (50 mg/kg) intravenously or orally to both rat models of diabetes and their respective control rats. RESULTS: After intravenous administration of telithromycin to both models of diabetes, the non-renal clearance (CLNR) was significantly faster (32.3 and 53.1% increase for rat models of DMIA and DMIS, respectively) and the AUC was significantly smaller (25.0 and 33.8% decrease, respectively) than those in their respective controls. However, after oral administration of telithromycin, the AUC was comparable to that in their respective controls. CONCLUSIONS: The faster CLNR after intravenous administration was due to increased hepatic CYP3A1/2 in both models of diabetes. The comparable AUC after oral administration was mainly due to decreased intestinal CYP3A1/2 activity. Alloxan and streptozotocin appear to influence some pharmacokinetics of telithromycin in a different fashion.
Assuntos
Antibacterianos/farmacocinética , Diabetes Mellitus Experimental/induzido quimicamente , Diabetes Mellitus Experimental/metabolismo , Cetolídeos/farmacocinética , Aloxano , Animais , Antibacterianos/administração & dosagem , Antibióticos Antineoplásicos , Área Sob a Curva , Proteínas Sanguíneas/metabolismo , Cromatografia Líquida de Alta Pressão , Diálise , Injeções Intravenosas , Mucosa Intestinal/metabolismo , Cetolídeos/administração & dosagem , Fígado/metabolismo , Masculino , Microssomos/metabolismo , Microssomos Hepáticos/metabolismo , Ligação Proteica , Ratos , Ratos Sprague-Dawley , EstreptozocinaRESUMO
BACKGROUND: Subinhibitory levels of clarithromycin and azithromycin have been shown to reduce the activity of bacterial virulence factors, but few studies have examined the effects of subinhibitory levels of telithromycin. Here, we examined the effects of telithromycin, clarithromycin and azithromycin on methicillin-resistant Staphylococcus aureus (MRSA) coagulase in vitro. We also examined the effects of these antibiotics on bacterial survival in a murine model of pulmonary infection, in which the number of bacteria in the lung correlates with the coagulase titre. METHODS: The coagulase titre in MRSA strain NUMR101, a clinical isolate, was measured after a 16 h treatment with telithromycin, clarithromycin or azithromycin at the MIC (512 mg/L) and 1/2, 1/4, 1/8 and 1/16 of the MIC. In addition, we examined the effect of these drugs in a murine model of pulmonary infection induced by the intravenous injection of S. aureus enmeshed in agar beads. Treatment was started 1 day before infection and mice were treated once a day for 7 days by oral administration of 10 or 100 mg/kg telithromycin, clarithromycin or azithromycin, and the number of viable bacteria in the lungs was counted 24 h after the injection of the bacteria. RESULTS: The coagulase titres in mice treated with 1/8 of the MIC of telithromycin, clarithromycin and azithromycin and in the control were 8, 4, 8 and 32, respectively. In the mouse model of infection, the log cfu/lung (mean +/- SEM; n = 5 or 6) were 6.62 +/- 0.81, 4.79 +/- 0.41, 6.15 +/- 0.38 and 8.41 +/- 0.30 for mice treated with 100 mg/kg/day of telithromycin, clarithromycin and azithromycin and for controls, respectively (P < 0.05 for all groups versus control). CONCLUSIONS: Subinhibitory concentrations of telithromycin inhibit MRSA coagulase in vitro. In addition, the in vivo results indicate that pre-treatment with telithromycin, clarithromycin or azithromycin can reduce the bacterial load in a murine model of pulmonary infection.
Assuntos
Azitromicina/administração & dosagem , Claritromicina/administração & dosagem , Coagulase/antagonistas & inibidores , Cetolídeos/administração & dosagem , Resistência a Meticilina/efeitos dos fármacos , Staphylococcus aureus/efeitos dos fármacos , Animais , Coagulase/metabolismo , Inibidores Enzimáticos/farmacologia , Humanos , Masculino , Resistência a Meticilina/fisiologia , Camundongos , Staphylococcus aureus/enzimologiaRESUMO
OBJECTIVES: We determined in vitro the potency of macrolides as P-glycoprotein inhibitors and tested in hospitalised patients whether coadministration of P-glycoprotein inhibitors leads to increased serum concentrations of the P-glycoprotein substrates digoxin and digitoxin. METHODS: In vitro, the effect of macrolides on polarised P-glycoprotein-mediated digoxin transport was investigated in Caco-2 cells. In a pharmacoepidemiological study, we analysed the serum digoxin and digitoxin concentrations with and without coadministration of P-glycoprotein inhibitors in hospitalised patients. RESULTS: All macrolides inhibited P-glycoprotein-mediated digoxin transport, with concentrations producing 50% inhibition (IC(50)) values of 1.8, 4.1, 15.4, 21.8 and 22.7 micromol/L for telithromycin, clarithromycin, roxithromycin, azithromycin and erythromycin, respectively. Coadministration of P-glycoprotein inhibitors was associated with increased serum concentrations of digoxin (1.3 +/- 0.6 vs 0.9 +/- 0.5 ng/mL, p < 0.01). Moreover, patients receiving macrolides had higher serum concentrations of cardiac glycosides (p < 0.05). CONCLUSION: Macrolides are potent inhibitors of P-glycoprotein. Drug interactions between P-glycoprotein inhibitors and substrates are likely to occur during hospitalisation.
Assuntos
Membro 1 da Subfamília B de Cassetes de Ligação de ATP/antagonistas & inibidores , Cardiopatias/metabolismo , Macrolídeos/farmacocinética , Membro 1 da Subfamília B de Cassetes de Ligação de ATP/fisiologia , Idoso , Idoso de 80 Anos ou mais , Alanina Transaminase/sangue , Aspartato Aminotransferases/sangue , Bilirrubina/sangue , Transporte Biológico , Células CACO-2 , Creatinina/sangue , Digitoxina/administração & dosagem , Digitoxina/sangue , Digitoxina/farmacocinética , Digoxina/administração & dosagem , Digoxina/sangue , Digoxina/farmacocinética , Interações Medicamentosas , Eritromicina/administração & dosagem , Eritromicina/farmacocinética , Feminino , Cardiopatias/sangue , Cardiopatias/fisiopatologia , Humanos , Pacientes Internados , Inulina/administração & dosagem , Inulina/sangue , Inulina/farmacocinética , Cetolídeos/administração & dosagem , Cetolídeos/farmacocinética , Macrolídeos/administração & dosagem , Masculino , Farmacoepidemiologia/métodosRESUMO
PURPOSE: To evaluate the pharmacokinetics of telithromycin after intravenous and oral administration and to find the reason for incomplete F value (first pass-effect) after intravenous, intraportal, intragastric, and intraduodenal administration to rats. METHODS: Telithromycin was administered intravenously or orally at doses of 20, 50, and 100 mg/kg to rats. And hepatic, gastric, and intestinal first-pass effects of telithromycin were also measured after intravenous, intraportal, intragastric, and intraduodenal administration at a dose of 50 mg/kg to rats. RESULTS: The dose-normalized AUC values of telithromycin were dose-dependent (increased with increasing doses) after both intravenous and oral dose ranges studied, possibly due to saturable metabolism of telithromycin. After oral administration (50 mg/kg), approximately 4.06% of oral dose was not absorbed, F was approximately 27.5%, and the intestinal first-pass effect was approximately 63.4% of oral dose. The first-pass effects of telithromycin in the lung, heart, stomach, and liver were almost negligible, if any, in rats. CONCLUSIONS: The low F of telithromycin at a dose of 50 mg/kg was mainly due to considerable intestinal first-pass effect, approximately 63.4% of oral dose, in rats.
Assuntos
Antibacterianos/farmacocinética , Mucosa Intestinal/metabolismo , Cetolídeos/farmacocinética , Administração Oral , Animais , Área Sob a Curva , Disponibilidade Biológica , Relação Dose-Resposta a Droga , Estabilidade de Medicamentos , Injeções Intravenosas , Cetolídeos/administração & dosagem , Rim/metabolismo , Fígado/metabolismo , Masculino , Ligação Proteica , Ratos , Ratos Sprague-Dawley , Albumina Sérica/metabolismoRESUMO
New antibiotics are required to have the antibacterial activity against doxycycline-resistant Orientia tsutsugamushi. An in vitro sensitivity study showed that telithromycin was more effective than erythromycin for Rickettsia, Bartonella, and Coxiella burnetii. In this prospective, open-label, randomized trial, we enrolled patients with mild-to-moderate scrub typhus. We compared the efficacy and safety of a 5-day telithromycin therapy with those of a 5-day doxycycline therapy at Chosun University Hospital or one of its two community-based affiliated hospitals (Jangheung Hospital and Cheomdan Hospital), which are all located in southwestern Korea, between September and December 2005. A total of 92 patients were randomly assigned to either the telithromycin group (n = 47) or the doxycycline group (n = 45). After the treatment, fever control time was 20.45 +/- 12.9 h in the telithromycin group and 22.60 +/- 21.44 h in the doxycycline group (P > 0.05). After the treatment, the cure rate was 100% in the telithromycin group and 97.8% in the doxycycline group (P > 0.05). Furthermore, there were no significant differences in time elapsed until such symptoms as headache, myalgia, and rash disappeared. No serious adverse events or death were noted following the treatment in both groups. There were no significant differences in adverse events. In conclusion, the efficacy and safety of a 5-day once-a-day regimen of 800 mg telithromycin were equivalent to those of a 5-day twice-a-day regimen of 100 mg doxycycline in patients with mild-to-moderate scrub typhus. Telithromycin could be considered a promising new antibacterial agent for patients with scrub typhus.
Assuntos
Tifo por Ácaros/tratamento farmacológico , Adulto , Idoso , Antibacterianos/administração & dosagem , Antibacterianos/efeitos adversos , Antibacterianos/uso terapêutico , Doxiciclina/administração & dosagem , Doxiciclina/efeitos adversos , Doxiciclina/uso terapêutico , Feminino , Humanos , Cetolídeos/administração & dosagem , Cetolídeos/efeitos adversos , Cetolídeos/uso terapêutico , Masculino , Pessoa de Meia-Idade , Tifo por Ácaros/microbiologia , Resultado do TratamentoRESUMO
It was reported that the expression of CYP3A1 increased in rats with acute renal failure induced by uranyl nitrate (rat model of U-ARF) compared with controls. It was shown that telithromycin was mainly metabolized via CYP3A1/2 in rats in this study. Hence, the pharmacokinetic parameters of telithromycin were compared after both intravenous and oral administration at a dose of 50 mg/kg to control rats and a rat model of U-ARF. After intravenous administration of telithromycin to rats with U-ARF, the AUC and renal clearance (Cl(r)) were significantly greater (35.0% increase) and slower (99.1% decrease), respectively, than the controls. Unexpectedly, the nonrenal clearance (Cl(nr)) of telithromycin was comparable between the two groups of rats, suggesting that CYP3A isozyme responsible for the metabolism of telithromycin seemed not to be expressed considerably in the rat model of U-ARF. After oral administration of telithromycin to rats with U-ARF, the AUC was also significantly greater (127% increase) than the controls and the value, 127%, was considerably greater than 35.0% after intravenous administration of telithromycin. This may be due mainly to the decrease in the intestinal first-pass effect of telithromycin compared with controls in addition to significantly slower Cl(r) than controls.
Assuntos
Injúria Renal Aguda/metabolismo , Antibacterianos/farmacocinética , Cetolídeos/farmacocinética , Injúria Renal Aguda/enzimologia , Administração Oral , Animais , Antibacterianos/administração & dosagem , Antibacterianos/metabolismo , Área Sob a Curva , Hidrocarboneto de Aril Hidroxilases/metabolismo , Citocromo P-450 CYP3A , Meia-Vida , Infusões Intravenosas , Isoenzimas/metabolismo , Cetolídeos/administração & dosagem , Cetolídeos/metabolismo , Masculino , Taxa de Depuração Metabólica , Ligação Proteica , Ratos , Ratos Sprague-DawleyRESUMO
BACKGROUND: Clarithromycin is commonly dosed for 7 or more days in patients with acute bacterial exacerbation of chronic bronchitis (ABECB). Studies with other antibiotics have shown equivalent efficacy, reduced/similar frequency of adverse events, improved adherence and patient satisfaction, and lower treatment costs with a shorter treatment course. PATIENTS AND METHODS: The study population was derived from two multicenter, randomized, double-blind (North America)/single-blind (France) comparative trials in which outpatients at least 35 years old with a presumptive diagnosis of obstructive ABECB were randomized to receive clarithromycin extended-release (ER) 1000 mg once daily for 5 days or a comparator agent--clarithromycin immediate-release (IR) 500 mg twice daily for 7 days (in North America) or telithromycin 800 mg once daily for 5 days (in France). RESULTS: A total of 818 patients were randomized (411 to clarithromycin ER and 407 to a comparator agent). The clinical cure rate in clinically evaluable patients at the follow-up visit was 90% each for the clarithromycin ER group (318/353) and the comparator group (318/355). The patient bacteriological cure rate and the overall target pathogen eradication rate in clinically and bacteriologically evaluable patients were each 92% for the clarithromycin ER group (155/168 and 189/205, respectively) and 93% for the comparator group (147/158 and 183/197, respectively) at the follow-up visit. The study drugs were generally well tolerated, with < 2% of patients discontinuing their treatment prematurely due to a drug-related adverse event. The incidence of drug-related adverse events was 18% (73/411) in the clarithromycin ER group and 24% (97/407) in the comparator group. Clarithromycin ER-treated patients reported statistically significantly fewer episodes of abdominal pain than did patients treated with a comparator agent (0.2% vs. 1.7%, respectively; p = 0.037). This combined analysis is limited by differing blinding methods, comparator agents, and their duration of administration. Furthermore, many patients were excluded from the clinically and bacteriologically evaluable group due to lack of a pretreatment target pathogen. CONCLUSION: A once daily, 5-day clarithromycin ER regimen appears to be a suitable choice for treating patients with ABECB.
Assuntos
Antibacterianos/administração & dosagem , Bronquite/tratamento farmacológico , Claritromicina/administração & dosagem , Doença Aguda , Idoso , Antibacterianos/efeitos adversos , Antibacterianos/uso terapêutico , Bronquite/microbiologia , Claritromicina/efeitos adversos , Claritromicina/uso terapêutico , Preparações de Ação Retardada , Progressão da Doença , Método Duplo-Cego , Esquema de Medicação , Feminino , Seguimentos , Humanos , Cetolídeos/administração & dosagem , Cetolídeos/efeitos adversos , Cetolídeos/uso terapêutico , Masculino , Pessoa de Meia-Idade , Projetos de Pesquisa , Índice de Gravidade de Doença , Escarro/microbiologia , Resultado do TratamentoRESUMO
OBJECTIVES: Bronchoscopic microsampling (BMS) is a new technique for repeated sampling of bronchial epithelial lining fluid (ELF) to obtain the pharmacokinetic profile of drugs. We analyzed the time versus concentration profiles of telithromycin in bronchial ELF obtained by BMS and compared these finding to those in plasma and alveolar ELF obtained by bronchoalveolar lavage (BAL). METHODS: Bronchial ELF samples were obtained from five healthy subjects using BMS probe at 0, 2, 3, 4, 6, 10 and 24h after single or multiple oral doses of 600 mg of telithromycin. Alveolar ELF was also obtained by BAL 3h after single or multiple oral doses of 600 mg of telithromycin. RESULTS: The areas under the concentration-time curve from 0 to 24h (AUC0-24) of telithromycin in plasma and bronchial ELF were 2.86+/-0.60 and 19.5+/-10.4 mg h/l after single treatment and 3.60+/-0.49 and 42.2+/-22.7 mg h/l after multiple treatments, respectively. Single and multiple oral doses of telithromycin produced significantly (p<0.05) higher AUC0-24 in bronchial ELF compared to those in plasma. While concentrations in bronchial ELF obtained by BMS were significantly lower than those in alveolar ELF obtained by BAL, they tended to be higher than those in plasma after multiple administration. The telithromycin concentrations obtained by BMS method were very consistent in bronchial ELF at different bronchi at one time point and at the same bronchus at different time points. CONCLUSIONS: Using the BMS technique, we could describe the pharmacokinetics of telithromycin in bronchial ELF. Furthermore, BMS was reasonably validated and reconfirmed to be a feasible and reliable method for measuring antimicrobial concentrations in bronchial ELF.